الفهرس 
indroductionOnly 14 pages are availabe for public view
 |  | from | 103 |  |  |
| | | from | 103 | | |
Abstract
Preparation of rabies vaccines, based on the election of inactivating agent, as the currently used one is Beta propiolactone (BPL), which is expensive and potentially carcinogenic, Ascorbic acid along with cupric ions proved its virucidal activity, and data indicated that Ascorbic acid (AA) was capable to induce a complete and irreversible inactivation of fixed rabies virus without adversely affecting its antigenicity. Ascorbic acid prepared vaccine was as potent as that prepared with BPL according to WHO recommendations; (ED50) >2.5 IU/dose. Vaccines stability was proved using different stabilizers (2% H. Albumin, 5% hemagel and 5%Lactose). Hemagel and H. Alb. Stabilized vaccine were potentially active than lactose stabilized one at different thermal conditions relatively to time. Immunization of laboratory animals with BPL and AA inactivated hemagel stabilized vaccines could induce higher antibody level, than those detected post immunization with BPL and AA inactivated vaccine candidates stabilized with lactose and H. albumin. The cellular immune response of vaccinated mice groups were evaluate by monitoring IFN-γ and IL-5 , result indicated that hemagel stabilized vaccine showed a significant elevated IFN-γ and IL-5 levels compared with vaccines stabilized with lactose and human albumin. Hemagel proved a good vaccine stability enhancer than the current stabilize.